Sanofi

Most Recent

  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Industry wise Return of FEZ on November
    Macroeconomic Analysis

    Reading Auto Manufacturing’s Outperformance on November 23

    The auto manufacturing industry provided a highest weighted return, at 0.085%, as well as the highest individual return, at 4.2%, on November 23.

    By Sarah Sands
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///eurozone PMI
    Macroeconomic Analysis

    Germany Helps Eurozone Business Activity Rise in August

    Both the manufacturing and service sector contributed positively to business activity growth in Germany in August.

    By Surbhi Jain
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///acquisition
    Company & Industry Overviews

    Medivation Is for Sale: How Much Should It Get?

    Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

    By Jillian Dabney
  • uploads///pharma challenges Japan
    Company & Industry Overviews

    What Are the Challenges for the Pharmaceutical Industry in Japan?

    Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

    By Jillian Dabney
  • uploads///Industry wise Performance Of the FEZ
    Macroeconomic Analysis

    Positive Manufacturing Reports Drive the FEZ Up

    The SPDR Euro Stoxx 50 ETF (FEZ) is a US exchange-traded ETF that tracks the performance of the 50 largest companies across the Eurozone.

    By Sarah Sands
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///MArket opportunity for Acthar
    Company & Industry Overviews

    Inside Mallinckrodt’s Major Valuation Catalysts

    Acthar is Mallinckrodt’s (MNK) leading product, and the company plans to achieve mid-single-digit to low-double-digit growth for the drug in fiscal 2016.

    By Jillian Dabney
  • uploads///dna _
    Earnings Report

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///addiction _
    Company & Industry Overviews

    Sanofi, Adaptive Biotechnologies Plan Multiple Myeloma Trials

    On May 29, Adaptive Technologies and Sanofi (SNY) formed a collaboration for a multiple myeloma trial.

    By Sarah Collins
  • uploads///Moving Average Analysis Of the FEZ On November th
    Macroeconomic Analysis

    FEZ’s Holdings: 65% Were above the 100-Day Moving Average

    On November 4, 65% of the SPDR Euro Stoxx 50 ETF’s (FEZ) portfolio holdings closed above the 100-day moving average—compared to 62% on November 3.

    By Sarah Sands
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///drug _
    Earnings Report

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Valuation Report Card: How Did It Score?

    The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Novartis Will Report Its 4Q15 Earnings on January 27

    Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.

    By Mike Benson
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///share price
    Earnings Report

    Understanding Regeneron’s Share Price Movement after Its 4Q15 Results

    Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Factors That Will Determine Repatha’s Future Commercial Success

    Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///joshua coleman  unsplash
    Earnings Report

    Sanofi Misses Wall Street Estimates for 1Q18 Revenues

    Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///dupixent sales
    Company & Industry Overviews

    Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials

    Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

    By Sarah Collins
  • uploads///Jenga
    Macroeconomic Analysis

    Hang Seng Ends Flat after Protests and Nikkei 225 Slides Again

    Hong Kong’s Hang Seng Index opened lower today and fell sharply in early trade in response to the political situation in the city. As life started getting back to normal in Hong Kong, the bulls returned and the index maintained upward momentum. The Hang Seng closed almost flat at the end of the session.

    By Mike Sonnenberg
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///biology _
    Company & Industry Overviews

    Why Sangamo Therapeutics Stock Is Down More than 22% Today

    Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.

    By Sarah Collins
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • uploads///long term debt
    Company & Industry Overviews

    Will Valeant be Able to Manage Its Huge Debt?

    With its acquisitions, Valeant’s long-term debt kept on swelling until it reached $30.2 billion at the end of 4Q15. It plans to repay $1.7 billion in 2016.

    By Jillian Dabney
  • When Is Sanofi Pharmaceutical Ingredient IPO Date
    Healthcare

    Sanofi Planning Pharma Ingredients IPO in Next Few Months

    By Ambrish Shah
  • glaxosmithkline and sanofi covid  vaccine to start human trials
    Healthcare

    GlaxoSmithKline and Sanofi Start Human Trials for COVID-19 Vaccine

    By Ambrish Shah
  • uploads///Generic Pharma Sales
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 1)

    Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]

    By VanEck
  • uploads///Chart  Ph
    Company & Industry Overviews

    Why GlaxoSmithKline’s Pharmaceuticals Business Grew

    GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Which of Amgen’s Drugs Could Witness Muted Growth in 2016?

    Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.

    By Margaret Patrick
  • uploads///Vaccine revenues
    Company & Industry Overviews

    How Pfizer’s Vaccine Franchise Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare and Generics Franchises

    Sanofi’s (SNY) Consumer Healthcare franchise’s products include Allegra, Doliprane, and Nasacort. The segment reported a 3.1% decline in revenues at 905 million euros in 1Q16, compared to its 1Q15 revenues.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Humira Continues to Be a Strong Growth Driver for AbbVie in 1Q16

    AbbVie (ABBV) has projected that Humira’s sales in 2016 will be higher than those reported by the drug in 2015 by around 15%–20% in the US.

    By Margaret Patrick
  • uploads///ZTS industry stats
    Consumer

    Must-know trends that drive Zoetis’ growth

    Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///part  aaple
    Company & Industry Overviews

    Key Changes in Berkshire Hathaway’s Holdings in Q3

    Looking at Berkshire Hathaway’s third-quarter 13F, the company added more Apple shares and added a new position in JPMorgan Chase.

    By Mohit Oberoi, CFA
  • uploads///Vaccines
    Company & Industry Overviews

    Pfizer’s Vaccines: A Look at Their Market Performance

    In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Shire: Why Analysts Expect Revenue Growth in Q3 2018

    Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

    By Mike Benson
  • uploads///drug _
    Earnings Report

    GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates

    Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”

    By Mike Benson
  • uploads///GBUs Q  performance
    Company & Industry Overviews

    Sanofi’s Organizational Restructuring: Investor Insights

    On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Was Flat in Second Quarter

    GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.

    By Mike Benson
  • uploads///product approval timeline
    Company & Industry Overviews

    Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent

    On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    A Look at Shire’s Valuation on September 19

    Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

    By Mike Benson
  • uploads///doctor _
    Company & Industry Overviews

    EC Approves GSK’s Nucala for Children with Severe Asthma

    On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Novartis’s SOLAR-1 Trial Met Primary Endpoint

    Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.

    By Mike Benson
  • uploads///Long acting
    Company & Industry Overviews

    Novo Nordisk’s Long-Acting Insulins: A Performance Overview

    Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.

    By Daniel Collins
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///syringe _
    Earnings Report

    GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates

    Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.

    By Mike Benson
  • uploads///Nplate
    Company & Industry Overviews

    How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18

    In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Analysts’ Recommendations for Eli Lilly and Peers in April

    In 1Q18, Eli Lilly (LLY) reported revenues close to $5.7 billion, which represents year-over-year growth of ~9.0%.

    By Margaret Patrick
  • uploads///Tresiba
    Company & Industry Overviews

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

    By Daniel Collins
  • uploads/// NON GAAP ADJUSTMENTS
    Company & Industry Overviews

    US Generics Market Consolidation Continues to Affect Teva

    In 4Q17, Teva experienced a price erosion of ~13% in its generics business.

    By Sarah Collins
  • uploads///Vaccine
    Company & Industry Overviews

    Behind Merck’s Vaccines Gardasil, Pneumovax 23, and ProQuad: A Post-4Q17 Performance Update

    In 4Q17, Merck’s Gardasil-Gardasil 9 generated revenues of $633 million, which reflected a ~17% rise on a YoY basis and a 6% fall on a QoQ basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Recent Developments from Novartis

    Novartis (NVS) reported 2% growth in operating revenues to ~$12.9 billion during 4Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Alcon Performed in 4Q17

    Alcon reported 8% growth in revenues to ~$1.6 billion during 4Q17 as compared to ~$1.4 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Business in 4Q17

    Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Expect for AstraZeneca Going Forward

    AstraZeneca surpassed Wall Street analysts’ estimates for EPS and revenues and reported EPS of $2.37 on revenues of ~$22.4 billion during 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Valuations in February 2018

    Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi Pasteur’s 4Q17 Performance

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17, reflecting 8.7% growth in operating revenues compared to 4Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17

    Sanofi’s consumer healthcare portfolio reported revenues of 1.2 billion euros in 4Q17, reflecting 51.8% growth in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Established Prescription Products in 4Q17

    Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Look at Sanofi Genzyme in 4Q17

    Sanofi Genzyme reported revenues of ~1.5 billion euros in 4Q17 for 16.8% growth in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Performance of Sanofi’s Business Segments in 4Q17

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

    By Mike Benson
  • uploads///Consumer
    Company & Industry Overviews

    JNJ’s Consumer Products: OTC, Women’s Health, and Wound Care

    In 4Q17, JNJ’s Women’s Health segment generated revenues of $262.0 million, which is an ~1.0% decline on a YoY basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    How Eli Lilly’s Cardiovascular Portfolio Performed in 4Q17

    Cardiovascular portfolio As discussed earlier, Eli Lilly and Company’s (LLY) human pharmaceutical business includes cardiovascular products Effient, Cialis, Adcirca, and Reopro. Revenue from Cialis, Effient, and Reopro fell in 4Q17, while Adcirca sales rose marginally. Effient The above chart shows Eli Lilly’s cardiovascular revenue since 1Q16. Effient, an antiplatelet drug approved for preventing blood clots in […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Valuations after Its 4Q17 Earnings

    On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Business Segments in 4Q17

    GSK’s Pharmaceuticals segment reported revenues of ~4.5 billion pounds during 4Q17, an ~1.0% decrease in revenues compared to 4Q16.

    By Mike Benson
  • uploads///SIP
    Company & Industry Overviews

    Behind Pfizer’s Sterile Injection Pharmaceutical Performance in 2017

    In fiscal 2017, Pfizer’s (PFE) Medrol generated revenues of $483 million, which was ~7% higher on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Vaccines
    Company & Industry Overviews

    Inside Pfizer’s Vaccines Performance in 4Q17 and 2017

    In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.